Document is current
Any future updates will be listed below
-
Authors
Tantalo, Daniela GM
Oliver, Amanda J
von Scheidt, Bianca
Harrison, Aaron J
Mueller, Scott N
Kershaw, Michael H
Slaney, Clare Y https://orcid.org/0000-0002-6986-6115
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01087294 at ClinicalTrials.govnct04217473 at ClinicalTrials.govDocuments that mention this clinical trial
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
https://doi.org/10.1136/jitc-2021-002555
Documents that mention this clinical trial
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
https://doi.org/10.1136/jitc-2021-002555
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
https://doi.org/10.1136/jitc-2025-sitc2025.0514
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
https://doi.org/10.1136/jitc-2023-sitc2023.0749
715 Emerging results from the use of an oncolytic adenovirus armed with TNFa and IL-2 (TILT-123) in different phase I solid tumor clinical trials
https://doi.org/10.1136/jitc-2022-sitc2022.0715
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)
https://doi.org/10.1136/jitc-2023-sitc2023.1518
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council
National Breast Cancer Foundation
- License Information
